Physician profile
Muhammad Irfan
NPI 1902851983
$2,475.98
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $28.20 · 2021: $318 · 2022: $709 · 2023: $756 · 2024: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $571.60 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $415.76 | 2019-2023 | Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $159.30 | 2021-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $140.92 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $136.16 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $132.36 | 2024 | Cobenfy |
| Axsome Therapeutics, INC. | $126.22 | 2022-2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $120.44 | 2019-2024 | Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.95 | 2023-2024 | Caplyta |
| Alkermes, INC. | $83.38 | 2021-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $83.32 | 2021-2023 | Rexulti |
| Corium, LLC | $72.19 | 2022-2023 | Azstarys |
| Neos Therapeutics, LP | $44.98 | 2022-2024 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $41.70 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $38.77 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $37.27 | 2019-2023 | Jornay Pm |
| Almatica Pharma LLC | $36.39 | 2021-2022 | |
| Bausch Health US, LLC | $31.15 | 2021-2022 | |
| Neuronetics, INC. | $20.60 | 2019 | |
| Tris Pharma INC | $18.75 | 2024 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $18.62 | 2021 | |
| Sun Pharmaceutical Industries INC. | $16.54 | 2021 | |
| Neurocrine Biosciences, INC. | $16.17 | 2023 | Ingrezza |
| Indivior INC. | $14.92 | 2022 | |
| Merck Sharp & Dohme LLC | $14.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Irfan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.